rozanolixizumab-noli (Rystiggo)

^[1]^[2]

Indications

generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive

↑ American Medical Association (AMA) AMA Morning Rounds. June 28, 2023
↑ ^2.0 ^2.1 ^2.2 Querol L, De Seze J, Dysgaard T et al Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study. J Neurol Neurosurg Psychiatry. 2024 May 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38729747 Free article. https://jnnp.bmj.com/content/early/2024/05/10/jnnp-2023-333112.long